Effects of Nutritional Intervention With Fish-derived Lipids in Improving Antiviral Immunity

Sponsor
Marinex International Sp. z o.o. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05502172
Collaborator
(none)
30
1
12

Study Details

Study Description

Brief Summary

The aim of the study is to evaluate the effects of fish-derived lipids on antiviral immunity in healthy individuals. The study will be conducted on a group of 30 healthy volunteers recruited at the Department of Periodontology and Oral Diseases of the Medical University of Lodz. These people will take a composition of fish-derived oils (BioMarine®Medical Immuno & Neuro Lipids) at a dose of 0.5 ml / kg body weight per day in two / three divided doses for 90 days. BioMarine®Medical Immuno & Neuro Lipids is food for special medical purposes. At baseline and after 90 days, blood samples will be taken from the test subjects in order to evaluate the selected parameters of antiviral immunity.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: fish oil
N/A

Detailed Description

The proposed clinical trial involving a nutritional intervention aims to assess the effect of a composition of fish oils containing, inter alia, WWKT omega-3 EPA and DHA, alkylglycerols and squalene on selected parameters of antiviral immunity in healthy people. The proposed daily dose of BioMarine®Medical Immuno & Neuro Lipids is 0.5 ml / kg b.w., which in practice for a person weighing 60 kg will mean a daily consumption of 30 mL of oil (including 1.6 g EPA, 9.1 g DHA, 2 5 g of alkylglycerols and 2.6 g of squalene).

At baseline, 15 ml of blood will be drawn in order to determine the parameters of the antiviral response.

The following immunological parameters will be tested:
  1. NK cell activity using a mixed culture of PBMC with target cells (ability to inhibit tumor cell proliferation) assessed by flow cytometry.

  2. Absolute number and percentage of NK cells (CD16 + CD56 +), cytotoxic (CD8 +), helper (CD4 +) lymphocytes, B (CD19 +) lymphocytes in the total pool of peripheral blood mononuclear cells (PBMC) by flow cytometry.

  3. Ability of isolated PBMCs to synthesize INF-α, INF-β, INF-γ, IL-6 and TNF without and after polyclonal stimulation (PHA) and SARS-CoV-2 proteins (nucleocapside protein, SARS-CoV-2 spike protein ) in 42 h culture based on the determination of the level of protein released into the culture fluid and on the basis of mRNA expression for these factors. Analysis of PBMC post-culture supernatants (CBA technique with flow cytometer and gene expression analysis by qPCR).

  4. Analysis of the composition of serum lipids and in PBMC lyophilisates after culture.

Blood sampling will be repeated after 90 days in order to determine the influence of the fish oils on the tested parameters.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Evaluation of the Effectiveness of Nutritional Intervention With Fish-derived Lipids in Improving Antiviral Immunity in Healthy People
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Mar 1, 2023
Anticipated Study Completion Date :
Sep 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: fish oil

Healthy individuals will be taking the composition of fish-derived oils BioMarine®Medical Immuno & Neuro Lipids at a dose of 0.5 ml / kg body weight per day in two / three divided doses for 90 days.

Dietary Supplement: fish oil
healthy individuals will be taking the composition of fish-deraivd oils BioMarine®Medical Immuno & Neuro Lipids at a dose of 0.5 ml / kg body weight per day in two / three divided doses for 90 days.
Other Names:
  • BioMarine®Medical Immuno&Neuro Lipids
  • Outcome Measures

    Primary Outcome Measures

    1. Change in peripheral blood NK cell activity [baseline, 90 days]

      NK cell activity using a mixed culture of PBMC with target cells (ability to inhibit tumor cell proliferation) assessed by flow cytometry.

    2. Change in the number and percentage of peripheral blood NK cells, CD8 cells, CD4 cells, CD19 cells [baseline, 90 days]

      Absolute number and percentage of NK cells (CD16 + CD56 +), cytotoxic (CD8 +), helper (CD4 +) lymphocytes, B (CD19 +) in the total pool of peripheral blood mononuclear cells (PBMC) by flow cytometry.

    3. Change in the production of cytokines (INF-α, INF-β, INF-γ, IL-6 and TNF) by peripheral blood mononuclear cells [baseline, 90 days]

      Ability of isolated PBMCs to synthesize INF-α, INF-β, INF-γ, IL-6 and TNF without and after polyclonal stimulation (PHA) and SARS-CoV-2 proteins (nucleocapside protein, SARS-CoV-2 spike protein ) in 42 h culture based on the determination of the level of protein released into the culture fluid and on the basis of mRNA expression for these factors. Analysis of PBMC post-culture supernatants (CBA technique with flow cytometer and gene expression analysis by qPCR).

    Secondary Outcome Measures

    1. Change in serum lipid content [baseline, 90 days]

      Analysis of lipid composition using gas/spectrum chromotography

    2. Change in in lipid content in PBMC lyophilisates [baseline, 90 days]

      Analysis of lipid composition using gas/spectrum chromotography

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 40 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • absence of systemic diseases;

    • no medications taken on a regular basis;

    • correct body weight in relation to height - 18.5 ≤ BMI ≤ 24.9

    Exclusion Criteria:
    • lack of consent the patient'sto the examination.

    • pregnant and lactating women;

    • smokers or non-smokers for less than 5 years;

    • any vaccinations in the period shorter than 1 month before the start of the study or planned during the study;

    • lack of declaration on reducing fats in the diet and avoiding highly processed fats and fried products.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Marinex International Sp. z o.o.

    Investigators

    • Principal Investigator: Natalia Lewkowicz, prof., Medical University of Lodz

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Natalia Lewkowicz, Professor, Medical University of Lodz
    ClinicalTrials.gov Identifier:
    NCT05502172
    Other Study ID Numbers:
    • RNN/52/22/KE
    First Posted:
    Aug 16, 2022
    Last Update Posted:
    Aug 19, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Natalia Lewkowicz, Professor, Medical University of Lodz

    Study Results

    No Results Posted as of Aug 19, 2022